A Blinded Placebo Controlled Single Ascending Dose Phase 1 for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Subcutaneous Administration of VRS-317 in Adults With Growth Hormone Deficiency
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Somavaratan (Primary)
- Indications Somatotropin deficiency
- Focus Adverse reactions
- Sponsors Versartis
- 23 Jun 2014 According to Versartis media release, the results of the trial were published in Journal of Clinical Endocrinology & Metabolism 2013.
- 11 Oct 2013 New trial record